



Rec'd PCT/PTO 10 MAR 2005  
PCT/GB 2003 / 0 0 3 9 3 7

09 SEPTEMBER 2003

INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 06 OCT 2003

WIPO PCT

BEST AVAILABLE COPY

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

CERTIFIED COPY OF  
PRIORITY DOCUMENT

Signed

Dated 7 August 2003

PRIORITY  
DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

1/77

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

THE PATENT OFFICE  
G  
13 SEP 2002  
NEWPORT

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference 100827-1
2. Patent application number  
(The Patent Office will fill in this part) 0221250.4 13 SEP 2002
3. Full name, address and postcode of the or of each applicant (underline all surnames) AstraZeneca AB  
S-151 85 Sodertalje  
Sweden  
  
Patents ADP number (if you know it) 7822448003  
  
If the applicant is a corporate body, give the country/state of its incorporation Sweden
4. Title of the invention COMPOUNDS
5. Name of your agent (if you have one) Hazel Potts  
  
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) AstraZeneca UK Limited  
Global Intellectual Property  
Mereside, Alderley Park  
Macclesfield  
Cheshire SK10 4TG  
  
Patents ADP number (if you know it) 7822471002
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number  

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application  

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description 50

Claim(s) 9

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Authorised Signatory

12/09/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer C Bennett - 01625 230148

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

The present invention relates to compounds useful in the inhibition of metalloproteinases and in particular to pharmaceutical compositions comprising these, as well  
5 as their use.

The compounds of this invention are inhibitors of one or more metalloproteinase enzymes and are particularly effective as inhibitors of TNF- $\alpha$  (Tumour Necrosis Factor- $\alpha$ ) Production. Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations  
10 these enzymes have been classified into families and subfamilies as described in N.M. Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMP) such as the collagenases (MMP1, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (MMP3, MMP10, MMP11), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMP19), the MT-MMPs (MMP14,  
15 MMP15, MMP16, MMP17); the reprolysin or adamalysin or MDC family which includes the secretases and sheddases such as TNF- $\alpha$  converting enzymes (ADAM10 and TACE); the ADAM-TS family (for example ADAM-TS1 and ADAM-TS4); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as the endothelin converting enzyme family and the angiotensin  
20 converting enzyme family.

Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin.  
25 Metalloproteinases are also believed to be important in the processing, or secretion, of biologically important cell mediators, such as tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem J. 321:265-279).

30 Metalloproteinases have been associated with many disease conditions. Inhibition of the activity of one or more metalloproteinases may well be of benefit in these disease conditions, for example: various inflammatory and allergic diseases such as, inflammation of

the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; and extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atherosclerosis.

A number of metalloproteinase inhibitors are known; different classes of compounds may have different degrees of potency and selectivity for inhibiting various metalloproteinases. We have discovered a class of compounds that are inhibitors of metalloproteinases and are of particular interest in inhibiting TACE. The compounds of this invention have beneficial potency and/or pharmacokinetic properties.

TACE (also known as ADAM17) which has been isolated and cloned [R.A. Black *et al.* (1997) *Nature* 385:729-733; M.L. Moss *et al.* (1997) *Nature* 385:733-736] is a member of the adamalysin family of metalloproteins. TACE has been shown to be responsible for the cleavage of pro-TNF- $\alpha$ , a 26kDa membrane bound protein to release 17kDa biologically active soluble TNF- $\alpha$ . [Schlondorff *et al.* (2000) *Biochem. J.* 347: 131-138]. TACE mRNA is found in most tissues, however TNF- $\alpha$  is produced primarily by activated monocytes, macrophages and T lymphocytes. TNF- $\alpha$  has been implicated in a wide range of pro-inflammatory biological processes including induction of adhesion molecules and chemokines to promote cell trafficking, induction of matrix destroying enzymes, activation of fibroblasts to produce prostaglandins and activation of the immune system [Aggarwal *et al.* (1996) *Eur. Cytokine Netw.* 7: 93-124]. Clinical use of the anti-TNF biologicals has shown TNF- $\alpha$  to play an important role in a range of inflammatory diseases including rheumatoid arthritis, Crohn's disease and psoriasis [Onrust *et al.* (1998) *Biodrugs* 10: 397-422, Jarvis *et al.* (1999) *Drugs* 57:945-964]. TACE activity has also been implicated in the shedding of other membrane bound proteins including TGF $\alpha$ , p75 & p55 TNF receptors, L-selectin and amyloid precursor protein - [Black (2002) *Int. J. Biochem. Cell Biol.* 34: 1-5]. The biology of TACE


inhibition has recently been reviewed and shows TACE to have a central role in TNF- $\alpha$  production and selective TACE inhibitors to have equal, and possibly greater, efficacy in the collagen induced arthritis model of RA than strategies that directly neutralise TNF- $\alpha$  [Newton et al (2001) Ann. Rheum. Dis. 60: iii25-iii32].

5 A TACE inhibitor might therefore be expected to show efficacy in all disease where TNF- $\alpha$  has been implicated including, but not limited to, inflammatory diseases including rheumatoid arthritis and psoriasis, autoimmune diseases, allergic/atopic diseases, transplant rejection and graft versus host disease, cardiovascular disease, reperfusion injury, malignancy and other proliferative diseases

10 We are able to provide compounds that have metalloproteinase inhibitory activity, and are in particular inhibitors of TACE (ADAM17).

According to the first aspect of the present invention there is provided a compound of formula (1), a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof:

15



formula (1)

wherein:

20 Y<sup>1</sup> and Y<sup>2</sup> are independently O or S;

Z is NR<sup>x</sup>, O or S;

n is 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are CR<sup>1</sup>R<sup>2</sup> or a bond;

m is 0 or 1;

D is hydrogen, C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl or fluoro;

5 X is  $-(CR^{12}R^{13})_t-Q-(CR^{14}R^{15})_u-$  where t and u are independently 0 or 1 and Q is O, S, SO or SO<sub>2</sub>;

B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl,

10 trifluoromethoxy, halo, cyano, C<sub>1-4</sub>alkyl (optionally substituted by R<sup>9</sup> or one or more halo), C<sub>2-4</sub>alkenyl (optionally substituted by halo or R<sup>9</sup>), C<sub>2-4</sub>alkynyl (optionally substituted by halo or R<sup>9</sup>), C<sub>3-6</sub>cycloalkyl (optionally substituted by R<sup>9</sup> or one or more halo), C<sub>5-6</sub>cycloalkenyl (optionally substituted by halo or R<sup>9</sup>), aryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heteroaryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heterocyclyl (optionally substituted by

15 C<sub>1-4</sub>alkyl), -SR<sup>11</sup>, -SOR<sup>11</sup>, -SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, -NR<sup>9</sup>SO<sub>2</sub>R<sup>11</sup>, -NHCONR<sup>9</sup>R<sup>10</sup>, -OR<sup>9</sup>, -NR<sup>9</sup>R<sup>10</sup>, -CONR<sup>9</sup>R<sup>10</sup> and -NR<sup>9</sup>COR<sup>10</sup>; or B is C<sub>2-4</sub>alkenyl or C<sub>2-4</sub>alkynyl, each being optionally substituted by a group selected from C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, -CONHR<sup>9</sup>, -CONR<sup>9</sup>R<sup>10</sup>, -SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, -

20 NR<sup>9</sup>SO<sub>2</sub>R<sup>11</sup>, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy; with the provisos that:

when n is 1 and W is NR<sup>1</sup>, CR<sup>1</sup>R<sup>2</sup> or a bond; or when n is 0 and W is CR<sup>1</sup>R<sup>2</sup>; then B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally

substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C<sub>1-4</sub>alkyl (optionally substituted by R<sup>9</sup> or one or more halo), C<sub>2-</sub>

25 <sub>4</sub>alkenyl (optionally substituted by halo or R<sup>9</sup>), C<sub>2-4</sub>alkynyl (optionally substituted by halo or R<sup>9</sup>), C<sub>3-6</sub>cycloalkyl (optionally substituted by R<sup>9</sup> or one or more halo), C<sub>5-6</sub>cycloalkenyl (optionally substituted by halo or R<sup>9</sup>), aryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heteroaryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heterocyclyl (optionally substituted by C<sub>1-4</sub>alkyl), -SR<sup>11</sup>, -SOR<sup>11</sup>, -SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, -NR<sup>9</sup>SO<sub>2</sub>R<sup>11</sup>, -NHCONR<sup>9</sup>R<sup>10</sup>, -OR<sup>9</sup>, -

30 NR<sup>9</sup>R<sup>10</sup>, -CONR<sup>9</sup>R<sup>10</sup> and -NR<sup>9</sup>COR<sup>10</sup>; or B is C<sub>2-4</sub>alkenyl or C<sub>2-4</sub>alkynyl, each being

optionally substituted by a group selected from C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano,

trifluoromethyl, trifluoromethoxy,  $-\text{CONHR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $\text{C}_{1-4}\text{alkyl}$  and  $\text{C}_{1-4}\text{alkoxy}$ ; and

when  $n$  is 0 and  $W$  is  $\text{NR}^1$  or a bond; then  $B$  is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or  
 5 more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $\text{C}_{1-4}\text{alkyl}$  (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{2-4}\text{alkenyl}$  (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{2-4}\text{alkynyl}$  (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{3-6}\text{cycloalkyl}$  (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{5-6}\text{cycloalkenyl}$  (optionally substituted by halo or  $\text{R}^9$ ), aryl (optionally substituted by halo or  $\text{C}_{1-4}\text{alkyl}$ ), heteroaryl (optionally substituted  
 10 by halo or  $\text{C}_{1-4}\text{alkyl}$ ), heterocyclyl (optionally substituted by  $\text{C}_{1-4}\text{alkyl}$ ),  $-\text{SR}^{11}$ ,  $-\text{SOR}^{11}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $-\text{NHCONR}^9\text{R}^{10}$ ,  $-\text{OR}^9$ ,  $-\text{NR}^9\text{R}^{10}$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ; or  $B$  is  $\text{C}_{2-4}\text{alkenyl}$  or  $\text{C}_{2-4}\text{alkynyl}$ , each being optionally substituted by a group selected from  $\text{C}_{1-4}\text{alkyl}$ ,  $\text{C}_{3-6}\text{cycloalkyl}$ , aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-\text{CONHR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $\text{C}_{1-4}\text{alkyl}$  and  $\text{C}_{1-4}\text{alkoxy}$ ;

$\text{R}^1$  and  $\text{R}^2$  are independently hydrogen or a group selected from  $\text{C}_{1-6}\text{alkyl}$ ,  $\text{C}_{2-6}\text{alkenyl}$ ,  $\text{C}_{2-6}\text{alkynyl}$ ,  $\text{C}_{3-6}\text{cycloalkyl}$  and  $\text{C}_{5-6}\text{cycloalkenyl}$  where the group may be optionally substituted by halo, cyano, nitro, hydroxy or  $\text{C}_{1-4}\text{alkoxy}$ ;

$\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen or a group selected from  $\text{C}_{1-6}\text{alkyl}$ ,  $\text{C}_{2-6}\text{alkenyl}$ ,  $\text{C}_{2-6}\text{alkynyl}$ ,  $\text{C}_{3-6}\text{cycloalkyl}$ ,  $\text{C}_{5-6}\text{cycloalkenyl}$ , aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-4}\text{alkyl}$ ,  $\text{C}_{2-4}\text{alkenyl}$ ,  $\text{C}_{2-4}\text{alkynyl}$ ,  $\text{C}_{3-6}\text{cycloalkyl}$  (optionally substituted by one or more  $\text{R}^{17}$ ), aryl (optionally substituted by one or more  $\text{R}^{17}$ ), heteroaryl (optionally substituted by one or more  $\text{R}^{17}$ ), heterocyclyl,  $-\text{OR}^{18}$ ,  $-\text{SR}^{19}$ ,  $-\text{SOR}^{19}$ ,  $-\text{SO}_2\text{R}^{19}$ ,  $-\text{COR}^{19}$ ,  $-\text{CO}_2\text{R}^{18}$ ,  $-\text{CONR}^{18}\text{R}^{20}$ ,  $-\text{NR}^{16}\text{COR}^{18}$ ,  $-\text{SO}_2\text{NR}^{18}\text{R}^{20}$  and  $-\text{NR}^{16}\text{SO}_2\text{R}^{19}$ ;

or  $\text{R}^1$  and  $\text{R}^3$  together with the nitrogen or carbon and carbon to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom



groups selected from NH, O, S, SO and SO<sub>2</sub> where the ring is optionally substituted by one or more C<sub>1-4</sub>alkyl;

5 or R<sup>3</sup> and R<sup>4</sup> together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO<sub>2</sub> where the ring is optionally substituted by one or more C<sub>1-4</sub>alkyl;

10 or R<sup>5</sup> and R<sup>6</sup> together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and SO<sub>2</sub> where the ring is optionally substituted by one or more C<sub>1-4</sub>alkyl;

15 R<sup>7</sup> is hydrogen or a group selected from C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, heteroalkyl, C<sub>3-7</sub>cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>3-7</sub>cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which R<sup>7</sup> may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano, C<sub>1-4</sub>alkyl, nitro, haloC<sub>1-4</sub>alkyl, heteroalkyl, aryl, heteroaryl, hydroxyC<sub>1-4</sub>alkyl, C<sub>3-7</sub>cycloalkyl, heterocyclyl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, carboxyC<sub>1-4</sub>alkyl, -OR<sup>21</sup>, -CO<sub>2</sub>R<sup>21</sup>, -SR<sup>25</sup>, -SOR<sup>25</sup>, -SO<sub>2</sub>R<sup>25</sup>, -NR<sup>21</sup>COR<sup>22</sup>, -CONR<sup>21</sup>R<sup>22</sup> and -NHCONR<sup>21</sup>R<sup>22</sup>;

20 or R<sup>3</sup> and R<sup>7</sup> together with the carbon atoms to which they are each attached and (CR<sup>5</sup>R<sup>6</sup>)<sub>n</sub> form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and SO<sub>2</sub> where the ring is optionally substituted on carbon or nitrogen by one or more C<sub>1-4</sub>alkyl;

25 R<sup>8</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl and haloC<sub>1-6</sub>alkyl;

R<sup>9</sup> and R<sup>10</sup> are independently hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

30 or R<sup>9</sup> and R<sup>10</sup> together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

R<sup>11</sup> is C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup> and R<sup>15</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl and C<sub>3-6</sub>cycloalkyl;

5 R<sup>16</sup> is hydrogen or C<sub>1-6</sub>alkyl;

R<sup>17</sup> is selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl and C<sub>1-6</sub>alkoxy;

R<sup>18</sup> is hydrogen or a group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-7</sub>cycloalkenyl, saturated  
10 heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is  
optionally substituted by one or more halo;

R<sup>19</sup> and R<sup>25</sup> are independently a group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-7</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl  
15 where the group is optionally substituted by one or more halo;

R<sup>20</sup> is hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

or R<sup>18</sup> and R<sup>20</sup> together with the nitrogen to which they are attached form a heterocyclic 4- to  
20 7- membered ring;

R<sup>21</sup> and R<sup>22</sup> are independently hydrogen, C<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl and  
benzoyl;

25 or R<sup>21</sup> and R<sup>22</sup> together with the nitrogen to which they are attached form a heterocyclic 5- to  
6- membered ring.

According to a second aspect of the invention there is provided a compound of formula (1), a  
pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof wherein:

30 Y<sup>1</sup> and Y<sup>2</sup> are independently O or S;

Z is NR<sup>8</sup>, O or S;

n is 0;

W is  $\text{NR}^1$  or a bond;

5

m is 0 or 1;

D is hydrogen,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{3-6}$ cycloalkyl or fluoro;

10 X is  $-(\text{CR}^{12}\text{R}^{13})_t-\text{Q}-(\text{CR}^{14}\text{R}^{15})_u-$  where t and u are independently 0 or 1 and Q is O, S, SO or  $\text{SO}_2$ ;

B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl,

15 trifluoromethoxy, halo, cyano,  $\text{C}_{1-4}$ alkyl (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{2-4}$ alkenyl (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{2-4}$ alkynyl (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{3-6}$ cycloalkyl (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{5-6}$ cycloalkenyl (optionally substituted by halo or  $\text{R}^9$ ), aryl (optionally substituted by halo or  $\text{C}_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $\text{C}_{1-4}$ alkyl), heterocyclyl (optionally substituted by

20  $\text{C}_{1-4}$ alkyl),  $-\text{SR}^{11}$ ,  $-\text{SOR}^{11}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $-\text{NHCONR}^9\text{R}^{10}$ ,  $-\text{OR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ;

$\text{R}^1$  is hydrogen or a group selected from  $\text{C}_{1-6}$ alkyl,  $\text{C}_{2-6}$ alkenyl,  $\text{C}_{2-6}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl and  $\text{C}_{5-6}$ cycloalkenyl where the group may be optionally substituted by halo, cyano, nitro, hydroxy

25 or  $\text{C}_{1-4}$ alkoxy;

$\text{R}^3$  and  $\text{R}^4$  are independently hydrogen or a group selected from  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{2-4}$ alkynyl,  $\text{C}_{3-5}$ cycloalkyl, pentenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro,

30 cyano, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{2-4}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl (optionally substituted by one or more  $\text{R}^{17}$ ), aryl (optionally substituted by one or more  $\text{R}^{17}$ ),

heteroaryl (optionally substituted by one or more  $R^{17}$ ), heterocyclyl,  $-OR^{18}$ ,  $-SR^{19}$ ,  $-SOR^{19}$ ,  $-SO_2R^{19}$ ,  $-CONR^{18}R^{20}$  and  $-NR^{16}COR^{18}$ ;

or  $R^1$  and  $R^3$  together with the nitrogen or carbon and carbon to which they are respectively  
 5 attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon or nitrogen by one or more  $C_{1-4}$ alkyl;

or  $R^3$  and  $R^4$  together form a carbocyclic or saturated heterocyclic 3- to 7-membered ring  
 10 optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon or nitrogen by one or more  $C_{1-4}$ alkyl;

$R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, heteroalkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-5}$ cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which  
 15  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, carboxy $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-SR^{25}$ ,  $-SOR^{25}$ ,  
 20  $-SO_2R^{25}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;

or  $R^3$  and  $R^7$  together with the carbon atoms to which they are each attached and  $(CR^5R^6)_n$  form a saturated carbocyclic or heterocyclic 5- or 6-membered ring;

25  $R^8$  is selected from hydrogen,  $C_{1-4}$ alkyl and halo $C_{1-4}$ alkyl;

$R^9$  and  $R^{10}$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

or  $R^9$  and  $R^{10}$  together with the nitrogen to which they are attached form a heterocyclic 4 to 6-  
 membered ring.

$R^{11}$  is  $C_{1-4}$ alkyl or  $C_{3-5}$ cycloalkyl;

$R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently selected from hydrogen,  $C_{1-4}$ alkyl and  $C_{3-4}$ cycloalkyl;

$R^{16}$  is hydrogen or  $C_{1-4}$ alkyl;

5

$R^{17}$  is selected from halo,  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl and  $C_{1-4}$ alkoxy;

$R^{18}$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl,  $C_{5-6}$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl where the group is

10 optionally substituted by one or more halo;

$R^{19}$  and  $R^{25}$  are independently a group selected from  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl,  $C_{5-6}$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl where the group is optionally substituted by one or more halo;

15

$R^{20}$  is hydrogen,  $C_{1-4}$ alkyl or  $C_{3-5}$ cycloalkyl;

or  $R^{18}$  and  $R^{20}$  together with the nitrogen to which they are attached form a heterocyclic 4- to 6- membered ring;

20

$R^{21}$  and  $R^{22}$  are independently hydrogen,  $C_{1-4}$ alkyl, halo $C_{1-4}$ alkyl, aryl, aryl $C_{1-4}$ alkyl and benzoyl;

or  $R^{21}$  and  $R^{22}$  together with the nitrogen to which they are attached form a heterocyclic 5- to

25 6- membered ring.

It is to be understood that, insofar as certain of the compounds of formula (1) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon or sulphur atoms, the invention includes in its definition any such optically active or  
30 racemic form which possesses metalloproteinases inhibition activity and in particular TACE inhibition activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically

active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

Compounds of formula (1) are therefore provided as enantiomers, diastereomers, geometric isomers and atropisomers.

5        Within the present invention it is to be understood that a compound of the formula (1) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which has metalloproteinases inhibition activity and in particular TACE inhibition activity and is not to be limited merely to  
10 any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.

It is also to be understood that certain compounds of the formula (1) and salts thereof  
15 can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which have metalloproteinases inhibition activity and in particular TACE inhibition activity.

It is also to be understood that certain compounds of the formula (1) may exhibit polymorphism, and that the invention encompasses all such forms which possess  
20 metalloproteinases inhibition activity and in particular TACE inhibition activity.

The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically  
25 acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include but are not limited to hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In addition where the compounds of formula (1) are sufficiently acidic, salts are base salts and examples  
30 include but are not limited to, an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine or tris-(2-hydroxyethyl)amine

The compounds of formula (1) may also be provided as *in vivo* hydrolysable esters. An *in vivo* hydrolysable ester of a compound of formula (1) containing carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol. Such esters can be identified by

- 5 administering, for example, intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluid.

Suitable pharmaceutically acceptable esters for carboxy include C<sub>1-6</sub>alkoxymethyl esters for example methoxymethyl, C<sub>1-6</sub>alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C<sub>3-8</sub>cycloalkoxycarbonyloxyC<sub>1-6</sub>alkyl esters for example  
 10 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C<sub>1-6</sub>alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such  
 15 as phosphate esters (including phosphoramidic cyclic esters) and  $\alpha$ -acyloxyalkyl ethers and related compounds which as a result of the *in-vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of  $\alpha$ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in-vivo* hydrolysable ester forming groups for hydroxy include C<sub>1-10</sub>alkanoyl, for example formyl, acetyl; benzoyl; phenylacetyl;  
 20 substituted benzoyl and phenylacetyl, C<sub>1-10</sub>alkoxycarbonyl (to give alkyl carbonate esters), for example ethoxycarbonyl; di-(C<sub>1-4</sub>)alkylcarbamoyl and *N*-(di-(C<sub>1-4</sub>)alkylaminoethyl)-*N*-(C<sub>1-4</sub>)alkylcarbamoyl (to give carbamates); di-(C<sub>1-4</sub>)alkylaminoacetyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C<sub>1-4</sub>)alkylaminomethyl and di-((C<sub>1-4</sub>)alkyl)aminomethyl, and morpholino or piperazino linked  
 25 from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting *in-vivo* hydrolysable esters include, for example, R<sup>A</sup>C(O)O(C<sub>1-6</sub>)alkyl-CO-, wherein R<sup>A</sup> is for example, benzyloxy-(C<sub>1-4</sub>)alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(C<sub>1-4</sub>)piperazino-(C<sub>1-4</sub>)alkyl, piperazino-(C<sub>1-4</sub>)alkyl and morpholino-(C<sub>1-4</sub>)alkyl.

30

In this specification the generic term "alkyl" includes both straight-chain and branched-chain-alkyl groups. However references to individual alkyl groups such as "propyl"

are specific for the straight chain version only and references to individual branched-chain alkyl groups such as *t*-butyl are specific for the branched chain version only. For example, "C<sub>1-4</sub>alkyl" includes methyl, ethyl, propyl, isopropyl, butyl and *t*-butyl and examples of "C<sub>1-6</sub>alkyl" include the examples of "C<sub>1-4</sub>alkyl" and additionally pentyl, 2,3-dimethylpropyl, 3-methylbutyl and hexyl. An analogous convention applies to other generic terms, for example "C<sub>2-4</sub>alkenyl" includes vinyl, allyl and 1-propenyl and examples of "C<sub>2-6</sub>alkenyl" include the examples of "C<sub>2-4</sub>alkenyl" and additionally 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-enyl, 3-methylbut-1-enyl, 1-pentenyl, 3-pentenyl and 4-hexenyl. Examples of "C<sub>2-4</sub>alkynyl" includes ethynyl, 1-propynyl, 2-propynyl and 3-butylnyl and examples of "C<sub>2-6</sub>alkynyl" include the examples of "C<sub>2-4</sub>alkynyl" and additionally 2-pentylnyl, hexynyl and 1-methylpent-2-ynyl. Where examples are given of generic terms, these examples are not limiting.

"Cycloalkyl" is a monocyclic, saturated alkyl ring. The term "C<sub>3-4</sub>cycloalkyl" includes cyclopropyl and cyclobutyl. The term "C<sub>3-5</sub>cycloalkyl" includes "C<sub>3-4</sub>cycloalkyl" and cyclopentyl. The term "C<sub>3-6</sub>cycloalkyl" includes "C<sub>3-5</sub>cycloalkyl" and cyclohexyl. The term "C<sub>3-7</sub>cycloalkyl" includes "C<sub>3-6</sub>cycloalkyl" and additionally cycloheptyl. The term "C<sub>3-10</sub>cycloalkyl" includes "C<sub>3-7</sub>cycloalkyl" and additionally cyclooctyl, cyclononyl and cyclodecyl.

"Cycloalkenyl" is a monocyclic ring containing 1, 2, 3 or 4 double bonds. Examples of "C<sub>5-6</sub>cycloalkenyl" are cyclopentenyl, cyclohexenyl and cyclohexadiene and examples of "C<sub>5-10</sub>cycloalkenyl" include the examples of "C<sub>5-6</sub>cycloalkenyl" and cyclooctatriene.

Unless otherwise specified "aryl" is monocyclic or bicyclic. Examples of "aryl" therefore include phenyl (an example of monocyclic aryl) and naphthyl (an example of bicyclic aryl).

Examples of "arylC<sub>1-4</sub>alkyl" are benzyl, phenethyl, naphthylmethyl and naphthylethyl.

Unless otherwise specified "heteroaryl" is a monocyclic or bicyclic aryl ring containing 5 to 10 ring atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen where a ring nitrogen or sulphur may be oxidised. Examples of heteroaryl are pyridyl, imidazolyl, quinolinyl, cinnolyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl and pyrazinyl. Preferably heteroaryl is pyridyl, imidazolyl, quinolinyl, pyrimidinyl, thienyl, pyrazolyl, thiazolyl, oxazolyl and isoxazolyl. More preferably heteroaryl is pyridyl, imidazolyl and pyrimidinyl. Examples of "monocyclic heteroaryl" are pyridyl, imidazolyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl,



oxazolyl, isoxazolyl and pyrazinyl. Examples of "bicyclic heteroaryl" are quinolinyl and cinnolinyl.

Examples of "heteroarylC<sub>1-4</sub>alkyl" are pyridylmethyl, pyridylethyl, pyrimidinylethyl, pyrimidinylpropyl, pyrimidinylbutyl, imidazolylpropyl, imidazolylbutyl, quinolinylpropyl, 5 1,3,4-triazolylpropyl and oxazolylmethyl.

"Heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic or bicyclic ring (unless otherwise stated) containing 4 to 12 atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH<sub>2</sub>- group can optionally be replaced by a -C(O)-; and where 10 (unless stated to the contrary) a ring nitrogen or sulphur atom is optionally oxidised to form the N-oxide or S-oxide(s); a ring -NH is optionally substituted by acetyl, formyl, methyl or mesyl; and the ring is optionally substituted by one or more halo. Examples and suitable values of the term "heterocyclyl" are piperidinyl, *N*-acetylpiperidinyl, *N*-methylpiperidinyl, *N*-formylpiperazinyl, *N*-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidyl, oxetanyl, 15 morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, pyranyl, dihydro-2*H*-pyranyl, tetrahydrofuranlyl, 2,5-dioximidazolidinyl, 2,2-dimethyl-1,3-dioxolanyl and 3,4-dimethylenedioxybenzyl. Preferred values are 3,4-dihydro-2*H*-pyran-5-yl, tetrahydrofuran-2-yl, 2,5-dioximidazolidinyl, 2,2-dimethyl-1,3-dioxolan-2-yl and 3,4-dimethylenedioxybenzyl. Examples of monocyclic heterocyclyl are piperidinyl, *N*-acetylpiperidinyl, *N*-methylpiperidinyl, *N*-formylpiperazinyl, *N*-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidyl, oxetanyl, morpholinyl, pyranyl, tetrahydrofuranlyl, 2,5-dioximidazolidinyl and 2,2-dimethyl-1,3-dioxolanyl. Examples of bicyclic heterocyclyl are tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl and 3,4-dimethylenedioxybenzyl. Examples of saturated heterocyclyl are piperidinyl, pyrrolidinyl and morpholinyl.

25 The term "halo" refers to fluoro, chloro, bromo and iodo.

Examples of "C<sub>1-4</sub>alkoxy" include methoxy, ethoxy, propoxy and isopropoxy.

Examples of "C<sub>1-6</sub>alkoxy" include the examples of "C<sub>1-4</sub>alkoxy" and additionally pentyloxy, 1-ethylpropoxy and hexyloxy.

"Heteroalkyl" is alkyl containing at least one carbon atom and having at least 30 one carbon atom replaced by a hetero group independently selected from N, O, S, SO, SO<sub>2</sub>, (a hetero group being a hetero atom or group of atoms).

Examples of "haloC<sub>1-4</sub>alkyl" include fluoromethyl, 1-chloroethyl, 2-chloroethyl, 2-bromopropyl, 1-fluoroprop-2-yl and 4-chlorobutyl. Examples of "haloC<sub>1-6</sub>alkyl" include the examples of "haloC<sub>1-4</sub>alkyl" and 1-chloropentyl, 3-chloropentyl and 2-fluorohexyl.

Examples of "hydroxyC<sub>1-4</sub>alkyl" include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxypropyl, 1-hydroxyprop-2-yl and 4-hydroxybutyl.

Example of "C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl" include methoxymethyl, ethoxymethyl, methoxyethyl, methoxypropyl and propoxybutyl.

Examples of "haloC<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl" include 1-(chloromethoxy)ethyl, 2-fluoroethoxymethyl, 2-(4-bromobutoxy)ethyl and 2-(2-iodoethoxy)ethyl.

Examples of "carboxyC<sub>1-4</sub>alkyl" include carboxymethyl, 2-carboxyethyl and 2-carboxypropyl.

A "carbocyclic 5 to 6-membered" ring is (unless specifically stated) a saturated, partially saturated or unsaturated ring containing 5 to 6 ring carbon atoms. Examples include cyclopentyl, cyclopent-3-enyl, cyclohexyl and cyclopent-2-enyl.

Heterocyclic rings are rings containing 1, 2 or 3 ring atoms selected from nitrogen, oxygen and sulphur. "Heterocyclic 5 to 7-membered" rings are pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl, homopiperazinyl, thiomorpholinyl, thiopyranyl and morpholinyl. "Heterocyclic 4 to 7-membered" rings include the examples of "heterocyclic 5 to 7-membered" and additionally azetidiny. Saturated heterocyclic 5- to 6-membered rings include piperidinyl, pyrrolidinyl and morpholinyl.

Where optional substituents are chosen from "one of more" groups or substituents it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. Preferably "one or more" means "1, 2 or 3" and this is particularly the case when the group or substituent is halo. "One or more" may also mean "1 or 2".

Compounds of the present invention have been named with the aid of computer software (ACD/Name version 5.09).

Preferred values of Y<sup>1</sup>, Y<sup>2</sup>, z, n, W, m, D, X, B, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as follows.

Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

In one aspect of the invention  $Y^1$  and  $Y^2$  are both O.

In another aspect  $Y^1$  and  $Y^2$  are both S.

In one aspect of the invention z is  $NR^8$ .

5

In one aspect of the invention n is 1.

In another aspect n is 0.

In one aspect of the invention W is  $NR^1$ ;

10 In another aspect W is  $CR^1R^2$ .

In a further aspect W is a bond.

In one aspect of the invention m is 0.

In another aspect of the invention m is 1.

15

In one aspect of the invention D is hydrogen, methyl or fluoro.

In another aspect D is hydrogen.

In one aspect of the invention X is  $-CR^{12}R^{13}-Q-$  or  $-CR^{12}R^{13}-Q-CR^{14}R^{15}-$ .

20 In another aspect of the invention X is  $-CR^{12}R^{13}-Q-$ ,  $-Q-CR^{14}R^{15}-$  or  $-CR^{12}R^{13}-Q-CR^{14}R^{15}-$ .

In another aspect X is Q.

In a further aspect X is  $-(CH_2)-O-$ ,  $-O-(CH_2)-$ ,  $-(CH_2)-O-(CH_2)-$  or  $-(CHMe)-O-$  or O.

25 In one aspect of the invention Q is O.

In one aspect of the invention, when n is 1 and W is  $NR^1$ ,  $CR^1R^2$  or a bond; or when n is 0 and W is  $CR^1R^2$ ; B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro,

30 trifluoromethyl, trifluoromethoxy, halo,  $C_{1-4}$ alkyl (optionally substituted by one or more halo),

$C_{2-4}$ alkynyl, heteroaryl,  $-OR^9$ , cyano,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_2$ -

$C_{1-4}$ alkenyl or  $C_{2-4}$ alkynyl optionally substituted by  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl or heterocyclyl.

In another aspect, when  $n$  is 1 and  $W$  is  $NR^1$ ,  $CR^1R^2$  or a bond; or when  $n$  is 0 and  $W$  is  $CR^1R^2$ ;  $B$  is phenyl, naphthyl, pyridyl, quinoliny, isoquinoliny, thieno[2,3-*b*]pyridyl, thieno[3,2-*b*]pyridyl, 1,8-naphthyridiny, 3,4-methylenedioxybenzyl, 1,6-naphthyridiny, thieno[2,3-*d*]pyrimidiny or thieno[3,2-*d*]pyrimidiny where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy halo,  $C_{1-4}$ alkyl (optionally substituted by one or more halo),  $C_{2-4}$ alkynyl, heteroaryl,  $-OR^9$ , cyano,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or  $B$  is vinyl or ethynyl optionally substituted by  $C_{1-4}$ alkyl.

10

In another aspect when  $n$  is 1 and  $W$  is  $NR^1$ ,  $CR^1R^2$  or a bond; or when  $n$  is 0 and  $W$  is  $CR^1R^2$ ;  $B$  is phenyl, naphthyl, pyridyl, quinoliny, isoquinoliny, thieno[2,3-*b*]pyridyl, thieno[3,2-*b*]pyridyl, 1,8-naphthyridiny, 3,4-methylenedioxybenzyl, 1,6-naphthyridiny, thieno[2,3-*d*]pyrimidiny or thieno[3,2-*d*]pyrimidiny where each is optionally substituted by one or more groups independently selected from trifluoromethyl, trifluoromethoxy, fluoro, chloro, bromo, methyl, isopropyl, ethynyl, cyano, acetamido, propyloxy, prop-2-yloxymethoxy, nitro, pyrrolidinylcarbonyl, *N*-propylcarbamoyl, pyrrolidinyl, piperidinyl, isoxazolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyrimidinyl and pyridyl; or  $B$  is vinyl or ethynyl optionally substituted by methyl or ethyl.

20

In a further aspect when  $n$  is 1 and  $W$  is  $NR^1$ ,  $CR^1R^2$  or a bond; or when  $n$  is 0 and  $W$  is  $CR^1R^2$ ;  $B$  is quinolin-4-yl, naphthyl, 2-methylquinolin-4-yl, 3-methylnaphthyl, 7-methylquinolin-5-yl, 6-methylquinolin-8-yl, 7-methylisoquinolin-5-yl, 6-methylthieno[2,3-*b*]pyridyl, 5-methylthieno[3,2-*b*]pyridyl, 2-methyl-1,8-naphthyridiny, 2-

25 trifluoromethylquinolin-4-yl, 2-ethynylquinolin-4-yl, 7-chloroquinolin-5-yl, 7-fluoro-2-methylquinolin-4-yl, 2-methyl-*N*-oxoquinolin-4-yl, 3-methylisoquinolin-1-yl, 5-fluoro-2-methylquinolin-4-yl, 2,6-dimethylpyrid-4-yl, 2,5-dimethylpyridin-4-yl, 2,5-dimethylphenyl, 3-methoxyphenyl, 2,5-difluorophenyl, 3,5-difluorophenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, 2,6-difluoro-3-methylphenyl, 2-chloro-6-fluorophenyl, 3-fluoro-6-methylphenyl, phenyl, 2-  
30 methylphenyl, 3-chlorophenyl, 2-bromophenyl, 2-fluorophenyl, 2,6-difluorophenyl, 3-fluorophenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 4-bromophenyl, 2-cyanophenyl, 4-fluorophenyl, 2-fluoro-3-methylphenyl, 4-methylphenyl, 2,4-

dichlorophenyl, 2,6-dichlorophenyl, 2,4,6-trimethylphenyl, 3-methylphenyl, 3,4-dimethylphenyl, 4-methoxyphenyl, 3,5-dimethylphenyl, 4-prop-2-ylphenyl, 3-chloro-4-methylphenyl, 3,4-methylenedioxybenzyl, 5-fluoro-2-methylpyridinyl, 2,4-dimethylphenyl, 1-methylquinolyl, 2-chloro-4-fluorophenyl, 2-chloro-4-trifluoromethylphenyl, 2-bromo-4,6-difluorophenyl, 2-bromo-4-fluorophenyl, 2,4-dichlorophenyl, 2-cyanophenyl, 2-bromophenyl, 2-chlorophenyl, 2-acetamidophenyl, 2-(prop-2-yloxy)phenyl, 2-trifluoromethylphenyl, 2-bromo-4-chlorophenyl, 2-methoxy-4-methylphenyl, 4-chloro-2-nitrophenyl, 4-methyl-2-nitrophenyl, 2,4-difluorophenyl, 2-nitrophenyl, 4-bromo-2-fluorophenyl, 2-methoxy-4-nitrophenyl, 2-(pyrrolidin-1-ylcarbonyl)phenyl, 2-chloro-4-nitrophenyl, 2-(*N*-prop-2-yl)carbamoylphenyl, 2-(pyrrolidin-1-yl)phenyl, 2-(piperidin-1-yl)phenyl, 4-bromo-2-methoxyphenyl, 2-fluoro-4-nitrophenyl, 2-chloro-4-bromophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-methoxyphenyl, 4-fluoro-2-methoxyphenyl, 2-fluoro-4-chlorophenyl, 4-fluoro-2-methylphenyl, 2-(isoxazol-5-yl)phenyl, 3-chloropyrid-2-yl, 7-chloroquinolin-4-yl, 3-cyanopyrid-2-yl, 8-chloroquinolin-4-yl, 3-trifluoromethylpyrid-2-yl, 3-chloro-5-trifluoromethylpyrid-2-yl, 3,5-dichloropyrid-2-yl, 6-chloroquinolin-4-yl, 5-methylthieno[2,3-*d*]pyrimidin-4-yl, 7-methylthieno[3,2-*d*]pyrimidin-4-yl, 8-fluoroquinolin-4-yl, 2-pyrazol-5-ylphenyl, 4-chloro-2-(isoxazol-5-yl)phenyl, 2-(isoxazol-5-yl)-4-trifluoromethylphenyl, 2-imidazol-5-ylphenyl, 2-(oxazol-5-yl)phenyl, 2-(thiazol-5-yl)phenyl, 2-(pyrimidin-2-yl)phenyl, 2-(pyrid-2-yl)phenyl, 6-fluoroquinolin-4-yl, 2-methylquinolin-4-yl, 6-chloro-2-methylquinolin-4-yl, 1,6-naphthyridin-4-yl, thieno[3,2-*b*]pyrid-7-yl, 5-fluoro-2-(isoxazol-5-yl)phenyl, 4-fluoro-2-(isoxazol-5-yl)phenyl, 4-chloro-2-trifluoromethylphenyl, 2-chloro-5-fluorophenyl, vinyl, ethynyl, prop-1-enyl, prop-1-ynyl or but-1-ynyl.

In one aspect of the invention, when *n* is 0 and *W* is  $\text{NR}^1$  or a bond; *B* is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo,  $\text{C}_{1-4}$ alkyl (optionally substituted by one or more halo),  $\text{C}_{2-4}$ alkynyl, heteroaryl,  $-\text{OR}^9$ , cyano,  $-\text{NR}^9\text{R}^{10}$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ; or *B* is  $\text{C}_{2-4}$ alkenyl or  $\text{C}_{2-4}$ alkynyl optionally substituted by  $\text{C}_{1-4}$ alkyl,  $\text{C}_{3-6}$ cycloalkyl or heterocyclyl.

30

In another aspect when *n* is 0 and *W* is  $\text{NR}^1$  or a bond; *B* is naphthyl, quinolyl, isoquinolyl, thieno[2,3-*b*]pyridyl, thieno[3,2-*b*]pyridyl, 1,8-naphthyridinyl, 3,4-

methylenedioxybenzyl, 1,6-naphthyridinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C<sub>1-4</sub>alkyl (optionally substituted by one or more halo), C<sub>2-4</sub>alkynyl, heteroaryl, -OR<sup>9</sup>, cyano, -NR<sup>9</sup>R<sup>10</sup>, -CONR<sup>9</sup>R<sup>10</sup> and -  
 5 NR<sup>9</sup>COR<sup>10</sup>; or B is vinyl or ethynyl optionally substituted by C<sub>1-4</sub>alkyl.

In another aspect when n is 0 and W is NR<sup>1</sup> or a bond; B is naphthyl, quinolinyl, isoquinolinyl, thieno[2,3-*b*]pyridyl, thieno[3,2-*b*]pyridyl, 1,8-naphthyridinyl, 3,4-methylenedioxybenzyl, 1,6-naphthyridinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl where each is optionally substituted by one or more groups independently selected from trifluoromethyl, trifluoromethoxy, fluoro, chloro, bromo, methyl, isopropyl, ethynyl, cyano, acetamido, propyloxy, prop-2-yl-oxy, methoxy, nitro, pyrrolidinylcarbonyl, *N*-propylcarbamoyl; or B is vinyl or ethynyl optionally substituted by methyl or ethyl.

15 In another aspect when n is 0 and W is NR<sup>1</sup> or a bond; B is quinolin-4-yl, naphthyl, 2-methylquinolin-4-yl, 3-methylnaphthyl, 7-methylquinolin-5-yl, 6-methylquinolin-8-yl, 7-methylisoquinolin-5-yl, 6-methylthieno[2,3-*b*]pyridyl, 5-methylthieno[3,2-*b*]pyridyl, 2-methyl-1,8-naphthyridinyl, 2-trifluoromethylquinolin-4-yl, 2-ethynylquinolin-4-yl, 7-chloroquinolin-5-yl, 7-fluoro-2-methylquinolin-4-yl, 2-methyl-*N*-oxoquinolin-4-yl, 3-  
 20 methylisoquinolin-1-yl, 5-fluoro-2-methylquinolin-4-yl, 3,4-methylenedioxybenzyl, 1-methylquinolinyl, 7-chloroquinolin-4-yl, 8-chloroquinolin-4-yl, 6-chloroquinolin-4-yl, 5-methylthieno[2,3-*d*]pyrimidin-4-yl, 7-methylthieno[3,2-*d*]pyrimidin-4-yl, 8-fluoroquinolin-4-yl, 6-fluoroquinolin-4-yl, 2-methylquinolin-4-yl, 6-chloro-2-methylquinolin-4-yl, 1,6-naphthyridin-4-yl, thieno[3,2-*b*]pyrid-7-yl, vinyl, ethynyl, prop-1-enyl, prop-1-ynyl or but-1-  
 25 ynyl.

In another aspect of the invention when n is 0 and W is NR<sup>1</sup> or a bond, then B is a group selected from aryl and heteroaryl where each group is optionally substituted by one or more groups independently selected from halo, C<sub>1-4</sub>alkyl (optionally substituted by one or more  
 30 halo), heteroaryl and C<sub>2-4</sub>alkynyl.

In another aspect of the invention B is a group selected from quinolinyl, pyridyl and phenyl

where each group is optionally substituted by one or more methyl, trifluoromethyl, trifluoromethoxy, halo or isoxazolyl.

In a further aspect of the invention B is 2-methylquinolin-4-yl, 2,5-dimethylphenyl or 2,5-dimethylpyrid-4-yl.

In one aspect of the invention  $R^1$  is hydrogen or methyl.

In one aspect of the invention  $R^2$  is hydrogen or methyl.

10

In one aspect of the invention  $R^3$  is hydrogen, methyl, propyl or phenyl.

In one aspect of the invention  $R^4$  is hydrogen or methyl.

15 In one aspect of the invention  $R^5$  is hydrogen or methyl.

In one aspect of the invention  $R^6$  is hydrogen or methyl.

In one aspect of the invention  $R^1$  and  $R^3$  together with the nitrogen or carbon and carbon to which they are respectively attached form a piperidine, pyrrolidine, piperazine, morpholine, cyclohexane or cyclopentane ring.

25 In one aspect of the invention  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_3$ -cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by heterocyclyl, aryl and heteroaryl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-NR^{21}COR^{22}$ ,  $-NR^{21}CO_2R^{22}$  and  $-CONR^{21}R^{22}$ .

30 In one aspect of the invention  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_3$ -cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by heterocyclyl, aryl and heteroaryl; and wherein the group from which  $R^7$  may be selected is

optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ , and  $NR^{21}CO_2R^{22}$ .

- 5 In another aspect  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, aryl $C_{1-4}$ alkyl, heteroaryl $C_{1-4}$ alkyl, heterocyclyl $C_{1-4}$ alkyl, aryl, heteroaryl, heterocyclyl and  $C_{3-5}$ cycloalkyl where the group is optionally substituted by cyano,  $C_{1-4}$ alkyl, halo,  $-OR^{21}$ ,  $-NR^{21}R^{22}$ ,  $-CO_2R^{21}$  and  $-NR^{21}CO_2R^{22}$ .
- 10 In a further aspect  $R^7$  is selected from hydrogen, methyl, ethyl, propyl, prop-2-yl, butyl, tert-butyl, 2-methylpropyl, 1-hydroxyethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-cyanoethyl, 2-aminoethyl, phenyl, pyridyl, benzyl, 3-methylbenzyl, phenylethyl, 4-chlorophenylethyl, 4-fluorophenylethyl, phenylpropyl, 4-chlorophenylpropyl, 4-fluorophenylpropyl, 4-methylpiperazin-1-ylethyl, morpholin-4-ylpropyl, pyrimidin-2-ylethyl, pyrimidin-2-ylpropyl,
- 15 pyrimidin-2-ylbutyl, 5-fluoropyrimidin-2-ylpropyl, imidazol-1-ylpropyl, imidazol-1-ylbutyl, 1,3,4-triazolylpropyl, piperidinyl, tetrahydro-2H-pyranyl, tetrahydro-2H-pyranylmethyl, pyrid-2-ylmethyl, pyrid-4-ylmethyl, pyrid-3-ylmethyl, piperidin-4-ylmethyl, N-(t-butoxycarbonyl)piperidin-4-yl, benzyloxyethyl, N-(t-butoxycarbonyl)piperidin-4-ylmethyl, (3,4,4-trimethyl-2,5-dioximidazolidin-1-yl)methyl and N-benzoyl-N-phenylaminomethyl.

20

In one aspect of the invention  $R^3$  and  $R^7$  together with the carbon atoms to which they are each attached and  $(CR^5R^6)_n$  form a piperidinyl, pyrrolidinyl, piperazine or morpholine ring.

In one aspect  $R^8$  is hydrogen or methyl.

25

In one aspect  $R^9$  is hydrogen or methyl.

In one aspect  $R^{10}$  is hydrogen or methyl.

In one aspect  $R^{11}$  is methyl.

In one aspect  $R^{12}$  is hydrogen or methyl.



In one aspect  $R^{13}$  is hydrogen or methyl.

---

In one aspect  $R^{14}$  is hydrogen or methyl.

5

In one aspect  $R^{15}$  is hydrogen or methyl.

In one aspect  $R^{16}$  is hydrogen or methyl.

10 In one aspect  $R^{17}$  is selected from fluoro, chloro, methyl or methoxy.

In one aspect of the invention  $R^{19}$  is a group selected from  $C_{1-6}$ alkyl, aryl and aryl $C_{1-4}$ alkyl where the group is optionally substituted by halo.

In another aspect  $R^{19}$  is a group selected from methyl, phenyl and benzyl where the group is  
15 optionally substituted by chloro.

In one aspect of the invention  $R^{19}$  is methyl.

In one aspect of the invention  $R^{18}$  is hydrogen or a group selected from  $C_{1-6}$ alkyl, aryl and aryl $C_{1-4}$ alkyl where the group is optionally substituted by halo.

20 In another aspect  $R^{18}$  is hydrogen or a group selected from methyl, phenyl and benzyl where the group is optionally substituted by chloro.

In one aspect  $R^{20}$  is hydrogen or methyl .

25 In one aspect  $R^{21}$  is hydrogen, methyl, ethyl, phenyl, benzyl and benzoyl.

In one aspect  $R^{22}$  is hydrogen, methyl, ethyl, phenyl, benzyl and benzoyl.

In another aspect  $R^{22}$  is hydrogen or methyl.

30 In one aspect of the invention  $R^{25}$  is a group selected from  $C_{1-6}$ alkyl, aryl and aryl $C_{1-4}$ alkyl where the group is optionally substituted by halo.

---

In another aspect  $R^{25}$  is a group selected from methyl, phenyl and benzyl where the group is optionally substituted by chloro.

In one aspect of the invention  $R^{25}$  is methyl.

5 A preferred class of compound is of the formula (1) wherein:

$Y^1$  and  $Y^2$  are both O.;

z is  $NR^8$ ;

n is 1;

W is  $NR^1$ ,  $CR^1R^2$  or a bond;

10 m is 1;

D is hydrogen, methyl or fluoro;

X is  $-CR^{12}R^{13}-Q-$ ,  $-Q-CR^{14}R^{15}-$ ,  $-CR^{12}R^{13}-Q-CR^{14}R^{15}-$  or Q;

Q is O;

B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally

15 substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl),

20 heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl and  $C_{1-4}$ alkoxy;

$R^1$  and  $R^2$  are independently hydrogen or methyl;

$R^3$  is hydrogen, methyl, ethyl or phenyl;

$R^4$ ,  $R^5$ ,  $R^6$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$  and  $R^{15}$  are independently hydrogen or methyl;

30  $R^{11}$  is methyl;

$R^{12}$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by heterocyclyl, aryl and heteroaryl; and

wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from

halo, cyano,  $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-NR^{21}COR^{22}$ ,  $-NR^{21}CO_2R^{22}$  and  $-CONR^{21}R^{22}$ ;

$R^{21}$  and  $R^{22}$  are independently hydrogen, methyl, ethyl, phenyl, benzyl and benzoyl.

5

Another preferred class of compound is of the formula (1) wherein:

$Y^1$  and  $Y^2$  are both O;

z is  $NR^8$ ;

n is 0;

10 W is  $CR^1R^2$ ;

m is 1;

D is hydrogen, methyl or fluoro;

X is  $-CR^{12}R^{13}-Q-$ ,  $-Q-CR^{14}R^{15}-$ ,  $-CR^{12}R^{13}-Q-CR^{14}R^{15}-$  or Q;

B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally

15 substituted by one or more groups independently selected from nitro, trifluoromethyl,

trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl),

20 heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by

$C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being

optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano,

25 trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl and  $C_{1-4}$ alkoxy;

$R^1$  and  $R^2$  are independently hydrogen or methyl;

$R^3$  is hydrogen, methyl, propyl or phenyl;

$R^4$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently hydrogen or methyl;

30  $R^{11}$  is methyl;

$R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or

heterocyclyl where the group is optionally substituted by heterocyclyl, aryl and heteroaryl; and

wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-NR^{21}COR^{22}$ ,  $-NR^{21}CO_2R^{22}$  and  $-CONR^{21}R^{22}$ ;  $R^{21}$  and  $R^{22}$  are independently hydrogen, methyl, ethyl, phenyl, benzyl and benzoyl.

5

Another preferred class of compound is of the formula (1) wherein:

$Y^1$  and  $Y^2$  are both O;

z is  $NR^8$ ;

n is 0;

10 W is  $NR^1$  or a bond;

m is 1;

D is hydrogen, methyl or fluoro;

X is  $-CR^{12}R^{13}-Q-$ ,  $-Q-CR^{14}R^{15}-$ ,  $-CR^{12}R^{13}-Q-CR^{14}R^{15}-$  or Q;

B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where

15 each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or

20  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, 25 nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl and  $C_{1-4}$ alkoxy;

$R^1$  is hydrogen;

$R^3$  is hydrogen, methyl, propyl or phenyl;

$R^4$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently hydrogen or methyl;

30  $R^{11}$  is methyl;

$R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by heterocyclyl, aryl and heteroaryl; and

wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-NR^{21}COR^{22}$ ,  $-NR^{21}CO_2R^{22}$  and  $-CONR^{21}R^{22}$ ;

$R^{21}$  and  $R^{22}$  are independently hydrogen, methyl, ethyl, phenyl, benzyl and benzoyl.

5

Another preferred class of compound is of the formula (1) wherein:

$Y^1$  and  $Y^2$  are both O;

z is  $NR^8$ ;

n is 0;

10 W is  $NR^1$  or a bond;

m is 1;

D is hydrogen, methyl or fluoro;

X is  $-CR^{12}R^{13}-Q-$ ,  $-Q-CR^{14}R^{15}-$  or  $-CR^{12}R^{13}-Q-CR^{14}R^{15}-$ ;

B is a group selected from aryl or heteroaryl where each group is optionally substituted by one

15 or more groups independently selected from halo,  $C_{1-4}$ alkyl (optionally substituted by one or more halo), heteroaryl and  $C_{2-4}$ alkynyl;

$R^1$  is hydrogen or methyl;

$R^3$  is hydrogen, methyl, ethyl or phenyl;

$R^4$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently hydrogen or methyl;

20  $R^{11}$  is methyl;

$R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by heterocyclyl, aryl and heteroaryl; and

wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from

25 halo, cyano,  $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ , and  $NR^{21}CO_2R^{22}$ ; and

$R^{21}$  and  $R^{22}$  are independently hydrogen, methyl, ethyl, phenyl, benzyl and benzoyl.


In another aspect of the invention, preferred compounds of the invention are any one of:

30 5-[(4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl)sulfonyl)methyl]-5-methylimidazolidine-2,4-dione; and

5-[(4-(2-methyl quinolin-4-yl methoxy)piperidin-1-yl)sulfonylmethyl]-5-methylimidazolidine-2,4-dione.

In another aspect the present invention provides a process for the preparation of a compound of formula (1) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof:

- a) converting a ketone or aldehyde of formula (2) into a compound of formula (1);



Scheme 1

and thereafter if necessary:


- i) converting a compound of the formula (1) into another compound of the formula (1);
- 15 ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

The hydantoin can be prepared by a number of methods for example;

- a) The aldehyde or ketone may be reacted with ammonium carbonate and potassium cyanide in aqueous alcohols using the method of Bucherer and Bergs (*Adv. Het. Chem.*, 1985, 38, 177).
- 20 b) The aldehyde or ketone can be first converted to the cyanohydrin and then further reacted with ammonium carbonate (*Chem. Rev.*, 1950, 56, 403).
- c) The aldehyde or ketone can be converted to the alpha-amino nitrile and then either
- 25 reacted with ammonium carbonate or aqueous carbon dioxide or potassium cyanate followed by mineral acid (*Chem. Rev.*, 1950, 56, 403).

The process may further comprise a process for the preparation of a ketone or aldehyde of formula (2) where W is a bond and n is 0 (indicated as a compound of formula (2')) which


process comprises reacting a sulphonamide of formula (3) with a compound of formula (4) where LG represents a leaving group such as halogen, alkoxy, or aryloxy.



Scheme 2

This process comprises the reaction of the sulphonamide of formula (3') with a base such as LHMDS or LDA in an inert solvent such as THF at temperatures from  $-78^\circ\text{C}$  to  $0^\circ\text{C}$  for 1 to 2h followed by addition of a compound of formula (4) at a temperature of  $-78^\circ\text{C}$  to room temperature for 1 to 24h.

A ketone of formula (2') may additionally be prepared by the process illustrated in Scheme 3:



Scheme 3


The silyl group present in the compound of formula (30) can be removed by TBAF.

Suitable leaving groups (L) are halo, mesyl and tosyl.

A suitable chlorinating agent is  $\text{POCl}_3$ .

- 20 A compound of formula (2') is prepared in the last stage by reacting the compound of formula (33) with the appropriate piperidine reagent.

Alternatively a process for the preparation of a ketone or aldehyde of formula (2) where W is a bond and n is 1 (indicated as a compound of formula (2'')) which process comprises reacting a sulphonamide of formula (3) with a compound of formula (5) (an epoxide or equivalent) to give an alcohol of formula (6) and oxidising the alcohol to give a ketone or aldehyde of formula (2'').




Scheme 4

10 More specifically the process of Scheme 4 comprises the steps of:

- reacting the sulphonamide of formula (3) with a base such as LDA or LHMDs in THF at a temperature of  $-78^{\circ}\text{C}$  to  $0^{\circ}\text{C}$  for 1 to 2h followed by addition of an epoxide or equivalent of formula (5) and reaction for 1 to 24h at a temperature of  $-78^{\circ}\text{C}$  to room temperature to give an alcohol of formula (6); and
- 15 oxidation of an alcohol of formula (6) to a ketone or aldehyde of formula (2''), suitable reagents are MnO<sub>2</sub>, PCC, PDC or DMSO/oxalyl chloride/TEA.

In another aspect of the invention there is provided a process for the preparation of a compound of formula (1) where W is NR<sup>1</sup>, R<sup>1</sup> is hydrogen and n is 0 (indicated as a compound of formula (1')) which process comprises reaction of a sulphamoyl chloride derivative of formula (7) with an amino-hydantoin derivative of formula (8).






Scheme 5

Suitable reaction conditions for such a transformation involve the addition of the sulphonyl chloride to the amino-hydantoin in an inert solvent such as DCM in the presence of a base such as TEA, pyridine or DIPEA at temperature of 0°C to 50°C.

Also provided is a process for the preparation of a hydantoin of formula (8) as shown in Scheme 6:

10



Scheme 6

The process of Scheme 6 comprises the steps of:

- 15 a) reacting dibenzylamine with a halo ketone or aldehyde of formula (9) in an inert solvent such as THF or DCM in the presence of a base e.g TEA at room temperature for 24h to give a protected amino ketone or aldehyde of formula (10);
- b) reaction of the ketone or aldehyde under hydantoin formation conditions to give a hydantoin of formula (11); and

- c) removal of the benzyl protecting groups by reaction with palladium/hydrogen to yield a hydantoin of formula (8).


Also provided is a process for the preparation of a sulphamoyl chloride of formula (7) as shown in Scheme 7.



Scheme 7

- 10 This reaction involves the treatment of a piperidine of formula (12) with sulphonyl chloride in inert solvent in the presence of a base such as TEA or DIPEA.

Also provided is a process for the preparation of a compound of formula (1) where  $W$  is  $NR^1$ ,  $R^1$  is hydrogen and  $n$  is 1 (indicated as a compound of formula (1')) which process comprises reacting a sulphamoyl chloride derivative of formula (7) with an amino-hydantoin derivative of formula (13).




Scheme 8

20

Suitable reaction conditions for such a transformation involve the addition of the sulphonyl chloride to the amino-hydantoin in an inert solvent such as DCM in the presence of a base such as TEA, pyridine or DIPEA at temperature of  $0^\circ\text{C}$  to  $50^\circ\text{C}$ .

- 25 Also provided is a process for the preparation of a hydantoin of formula (13), where  $R^6$  is hydrogen as shown in Scheme 9:



Scheme 9


5 The process of Scheme 9 comprises the steps of:

- a) reacting an enone of formula (14) with phthalimide in the presence of sodium methoxide in a polar solvent such as DMSO to give an N-substituted phthalimide of formula (15);
- b) formation of the hydantoin of formula (16) using e.g. ammonium carbonate and potassium cyanide in aqueous alcohols; and
- 10 c) removing the phthalimide residue e.g. by reacting with HCl in acetic acid to yield a hydantoin of formula (13)

In another aspect of the invention, there is provided a process for the preparation of  
 15 compounds of formula (3) (see Scheme 2 and 4) which process is outlined in Scheme 10 and comprises;

- a) reacting a compound of formula (16) with a compound of formula (17) in the presence of a base to deprotonate the compound of formula (17), to yield a compound of formula (18);
- 20 b) removing the protecting group (PG) from the compound of formula (18) is removed to yield a compound of formula (19); wherein X is  $-(CR^9R^{10})_r-Q-(CR^{11}R^{12})_u-$ ;

- c) reacting the compound of formula (19) with a suitable reagent to yield a compound of formula (3);




Scheme 10

In Scheme 10:

- L is a suitable leaving group such as halo (chloro, bromo, iodo), mesyl, tosyl.
- Formula (17) can be deprotonated with a base such as NaH, LDA, BuLi, LHMDS and reacted with Formula (16) at temperatures ranging from  $-78^{\circ}\text{C}$  to  $70^{\circ}\text{C}$  in an aprotic solvent, e.g. THF under argon.
- Suitable protecting groups (PG) include Boc (t-butoxycarbonyl), CBz (carbonyloxybenzyl) groups and mesyl or another alkylsulphonyl-. In the case where PG is alkylsulphonyl-, reaction of formula (16) and formula (17) directly produce a compound of formula (3).
- A compound of formula (18) can be converted to a compound of formula (19) by treatment with acid (Boc) or hydrogen/ palladium (CBz).
- A compound of formula (19) can be converted to a compound of formula (3) by treatment with an alkylsulphonylchloride in the presence of a base such as pyridine in a solvent such as DCM.

A compound of formula (3) can also be prepared by a process as outlined in Scheme 11, which comprises;

- a) reacting a compound of formula (20) with a compound of formula (21), in the presence of a base to yield a compound of formula (18);
- b) removing the protecting group (PG) from the compound of formula (18) to yield a compound of formula (19);
- 5 c) reacting the compound of formula (19) with a suitable reagent to yield a compound of formula (3); and
- d) oxidising Q as required.



Scheme 11

In both schemes 10 and 11:

- L is a suitable leaving group such as halo (chloro, bromo, iodo), hydroxy, mesyl, nosyl and tosyl.
- Suitable bases to deprotonate compounds of formula (17) and formula (20) include bases such as CsF, NaH, LDA, BuLi, and LHMDS.
- Suitable reaction conditions for a) are temperatures ranging from  $-78^{\circ}\text{C}$  to  $70^{\circ}\text{C}$  and in aprotic solvent, e.g. THF under argon.
- Suitable protecting groups (PG) include Boc (t-butoxycarbonyl), CBz (carbonyloxybenzyl) groups and mesyl or another alkylsulphonyl-. In the case where PG is alkylsulphonyl-, reaction of formula (16) and (17) and of formula (20) and formula (21) directly produces a compound of formula (3).
- A compound of formula (18) can be converted to a compound formula (19) by treatment with acid (Boc) or hydrogen/ palladium (CBz).

- A compound of formula (19) can be converted to a compound of formula (3) by treatment with an alkylsulphonylchloride in the presence of a base such as pyridine in a solvent such as DCM.
- When B is aromatic, X is O and L is OH, Mitsunobu conditions can be used to form a compound of formula (18), i.e. a compound of formula (16) or formula (20) is reacted with a mixture of DEAD or DIAD and triphenylphosphine and formula (17) or formula (21) to give a compound of formula (3).

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogen group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possesses metalloproteinases inhibitory activity, and in particular TACE inhibitory activity. This property may be assessed, for example, using the procedure set out below.

## 5 Isolated Enzyme Assays

### Matrix Metalloproteinase family including for example MMP13.

Recombinant human proMMP13 may be expressed and purified as described by Knauper *et al.* [V. Knauper *et al.*, (1996) *The Biochemical Journal* 271:1544-1550 (1996)].

- 10 The purified enzyme can be used to monitor inhibitors of activity as follows: purified proMMP13 is activated using 1mM amino phenyl mercuric acid (APMA), 20 hours at 21°C; the activated MMP13 (11.25ng per assay) is incubated for 4-5 hours at 35°C in assay buffer (0.1M Tris-HCl, pH 7.5 containing 0.1M NaCl, 20mM CaCl<sub>2</sub>, 0.02 mM ZnCl and 0.05% (w/v) Brij 35 using the synthetic substrate 7-methoxycoumarin-4-
- 15 yl)acetyl.Pro.Leu.Gly.Leu.N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl.Ala.Arg.NH<sub>2</sub> in the presence or absence of inhibitors. Activity is determined by measuring the fluorescence at  $\lambda_{ex}$  328nm and  $\lambda_{em}$  393nm. Percent inhibition is calculated as follows: % Inhibition is equal to the [Fluorescence<sub>plus inhibitor</sub> - Fluorescence<sub>background</sub>] divided by the [Fluorescence<sub>minus inhibitor</sub> - Fluorescence<sub>background</sub>].
- 20 A similar protocol can be used for other expressed and purified pro MMPs using substrates and buffers conditions optimal for the particular MMP, for instance as described in C. Graham Knight *et al.*, (1992) *FEBS Lett.* 296(3):263-266.

### Adamalysin family including for example TNF convertase

- 25 The ability of the compounds to inhibit proTNF- $\alpha$  convertase enzyme (TACE) may be assessed using a partially purified, isolated enzyme assay, the enzyme being obtained from the membranes of THP-1 as described by K. M. Mohler *et al.*, (1994) *Nature* 370:218-220. The purified enzyme activity and inhibition thereof is determined by incubating the partially purified enzyme in the presence or absence of test compounds using the substrate
- 30 4',5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Ala.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid-1-yl)-fluorescein)-NH<sub>2</sub> in assay buffer (50mM Tris HCl, pH 7.4 containing 0.1% (w/v) Triton X-100 and 2mM CaCl<sub>2</sub>), at 26°C for 4 hours. The amount of inhibition is



determined as for MMP13 except  $\lambda_{ex}$  485nm and  $\lambda_{em}$  538nm were used. The substrate was synthesised as follows. The peptidic part of the substrate was assembled on Fmoc-NH-Rink-MBHA-polystyrene-resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at least a 4- or 5-fold excess of Fmoc-amino acid and HBTU. Ser<sup>1</sup> and Pro<sup>2</sup> were double-coupled. The following side chain protection strategy was employed; Ser<sup>1</sup>(But), Gln<sup>5</sup>(Trityl), Arg<sup>8,12</sup>(Pmc or Pbf), Ser<sup>9,10,11</sup>(Trityl), Cys<sup>13</sup>(Trityl). Following assembly, the N-terminal Fmoc-protecting group was removed by treating the Fmoc-peptidyl-resin with in DMF. The amino-peptidyl-resin so obtained was acylated by treatment for 1.5-2hr at 70°C with 1.5-2 equivalents of 4',5'-dimethoxy-fluorescein-4(5)-carboxylic acid [Khanna & Ullman, (1980) Anal Biochem. 108:156-161) which had been preactivated with diisopropylcarbodiimide and 1-hydroxybenzotriazole in DMF]. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane. The dimethoxyfluoresceinyl-peptide was isolated by evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid. The product was characterised by MALDI-TOF MS and amino acid analysis.

20

### Natural Substrates

The activity of the compounds of the invention as inhibitors of aggrecan degradation may be assayed using methods for example based on the disclosures of E. C. Arner *et al.*, (1998) Osteoarthritis and Cartilage 6:214-228; (1999) Journal of Biological Chemistry, 274:10, 6594-6601 and the antibodies described therein. The potency of compounds to act as inhibitors against collagenases can be determined as described by T. Cawston and A. Barrett (1979) Anal. Biochem. 99:340-345.

25

### Inhibition of metalloproteinase activity in cell/tissue based activity

#### 30 Test as an agent to inhibit membrane sheddases such as TNF convertase

The ability of the compounds of this invention to inhibit the cellular processing of TNF- $\alpha$  production may be assessed in THP-1 cells using an ELISA to detect released TNF-

essentially as described K. M. Mohler *et al.*, (1994) Nature 370:218-220. In a similar fashion the processing or shedding of other membrane molecules such as those described in N. M. Hooper *et al.*, (1997) Biochem. J. 321:265-279 may be tested using appropriate cell lines and with suitable antibodies to detect the shed protein.

5

#### **Test as an agent to inhibit cell based invasion**

The ability of the compound of this invention to inhibit the migration of cells in an invasion assay may be determined as described in A. Albini *et al.*, (1987) Cancer Research 47:3239-3245.

10

#### **Test as an agent to inhibit whole blood TNF sheddase activity**

The ability of the compounds of this invention to inhibit TNF- $\alpha$  production is assessed in a human whole blood assay where LPS is used to stimulate the release of TNF- $\alpha$ . 160 $\mu$ l of heparinized (10Units/ml) human blood obtained from volunteers, was added to the plate and  
15 incubated with 20 $\mu$ l of test compound (duplicates), in RPMI1640 + bicarbonate, penicillin, streptomycin, glutamine and 1% DMSO, for 30 min at 37°C in a humidified (5%CO<sub>2</sub>/95%air) incubator, prior to addition of 20 $\mu$ l LPS (E. coli. 0111:B4; final concentration 10 $\mu$ g/ml). Each assay includes controls of neat blood incubated with medium alone or LPS (6 wells/plate of each). The plates are then incubated for 6 hours at 37°C (humidified incubator), centrifuged  
20 (2000rpm for 10 min; 4°C ), plasma harvested (50-100 $\mu$ l) and stored in 96 well plates at -70°C before subsequent analysis for TNF- $\alpha$  concentration by ELISA.

#### **Test as an agent to inhibit in vitro cartilage degradation**

The ability of the compounds of this invention to inhibit the degradation of the  
25 aggrecan or collagen components of cartilage can be assessed essentially as described by K. M. Bottomley *et al.*, (1997) Biochem J. 323:483-488.

#### **In vivo assessment**

##### **Test as an anti-TNF agent**

30 The ability of the compounds of this invention as *in vivo* TNF- $\alpha$  inhibitors is assessed in the following manner. Briefly, groups of female Wistar Alderley Park (AP) rats (90-100g) are dosed with compound (5 rats) or drug vehicle (5 rats) by the appropriate route e.g. peroral (p.o.),

intraperitoneal (i.p.), subcutaneous (s.c.) 1 hour prior to lipopolysaccharide (LPS) challenge (30µg/rat i.v.). Sixty minutes following LPS challenge rats are anaesthetised and a terminal blood sample taken via the posterior vena cavae. Blood is allowed to clot at room temperature for 2 hours and serum samples obtained. These are stored at -20°C for TNF-α ELISA and

5 compound concentration analysis.

Data analysis by dedicated software calculates for each compound/dose:

$$\text{Percent inhibition of TNF-}\alpha = \frac{\text{Mean TNF-}\alpha \text{ (Vehicle control)} - \text{Mean TNF-}\alpha \text{ (Treated)} \times 100}{\text{Mean TNF-}\alpha \text{ (Vehicle control)}}$$

10

### Test as an anti-arthritic agent

Activity of a compound as an anti-arthritic is tested in the collagen-induced arthritis (CIA) as defined by D. E. Trentham *et al.*, (1977) J. Exp. Med. 146,:857. In this model acid soluble native type II collagen causes polyarthritis in rats when administered in Freund's

15 incomplete adjuvant. Similar conditions can be used to induce arthritis in mice and primates.

### Pharmaceutical Compositions

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (1), or a pharmaceutically

20 acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical

25 administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably 0.5

30 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease.

condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

5 Therefore in a further aspect of the present invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treatment of a warm-blooded animal such as man by therapy.

Also provided is a compound of the formula (1), or a pharmaceutically acceptable salt  
10 or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of treating a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF- $\alpha$ .

Further provided is a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use in a method of  
15 treating inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man. In particular a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use in a method of treating rheumatoid arthritis, Crohn's disease and psoriasis,  
20 and especially rheumatoid arthritis.

According to an additional aspect of the invention there is provided a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament.

Also provided is a compound of the formula (1), or a pharmaceutically acceptable salt  
25 or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF- $\alpha$ .

Further provided is a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, for use as a medicament in  
30 the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy. In particular a compound of the formula

(1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided for use as a medicament in the treatment of rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis.

---

5        According to this another aspect of the invention there is provided the use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of a disease condition mediated by one or more metalloproteinase enzymes and in particular a disease condition mediated by TNF- $\alpha$  in a warm-blooded animal such as man.

10       Also provided is the use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the treatment of inflammatory diseases, autoimmune diseases, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal such as man. In  
15       particular the use of a compound of the formula (1), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore, is provided in the manufacture of a medicament in the treatment of rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis.

20       According to a further feature of this aspect of the invention there is provided a method of producing a metalloprotenase inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

25       According to a further feature of this aspect of the invention there is provided a method of producing a TACE inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

30       According to this further feature of this aspect of the invention there is provided a method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

---

Also provided is a method of treating rheumatoid arthritis, Crohn's disease and psoriasis, and especially rheumatoid arthritis in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (1).

5

In addition to their use in therapeutic medicine, the compounds of formula (1) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

15 The compounds of this invention may be used in combination with other drugs and therapies used in the treatment of various immunological, inflammatory or malignant disease states which would benefit from the inhibition of TACE.

If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically-active agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate.

### Examples

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
- (ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals; 4.5-30 mm Hg) with a bath temperature of up to 60°C;
- (iii) chromatography unless otherwise stated means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; where a "Bond Elut" column

is referred to, this means a column containing 10g or 20g of silica of 40 micron particle size, the silica being contained in a 60ml disposable syringe and supported by a porous disc,

obtained from Varian, Harbor City, California, USA under the name "Mega-Bond-Elut-SI".

Where an "Isolute<sup>TM</sup> SCX column" is referred to, this means a column containing

5 benzenesulphonic acid (non-encapped) obtained from International Sorbent Technology Ltd., 1st House, Duffryn Industrial Estate, Ystrad Mynach, Hengoed, Mid Glamorgan, UK. Where Flashmaster II is referred to, this means a UV driven automated chromatography unit supplied by Jones;

(iv) in general, the course of reactions was followed by TLC and reaction times are given for  
10 illustration only;

(v) yields, when given, are for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;

(vi) when given, <sup>1</sup>H NMR data is quoted and is in the form of delta values for major  
15 diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 400 MHz using perdeuterio DMSO (CD<sub>3</sub>SOCD<sub>3</sub>) as the solvent unless otherwise stated; coupling constants (J) are given in Hz;

(vii) chemical symbols have their usual meanings; SI units and symbols are used;

(viii) solvent ratios are given in percentage by volume;

20 (ix) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (APCI) mode using a direct exposure probe; where indicated ionisation was effected by electrospray (ES); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)<sup>+</sup>;

25 (x) LCMS characterisation was performed using a pair of Gilson 306 pumps with Gilson 233 XL sampler and Waters ZMD4000 mass spectrometer. The LC comprised water symmetry 4.6x50 column C18 with 5 micron particle size. The eluents were: A, water with 0.05% formic acid and B, acetonitrile with 0.05% formic acid. The eluent gradient went from 95% A to 95% B in 6 minutes. Where indicated ionisation was effected by electrospray (ES); where


30 values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)<sup>+</sup> and

(xi) the following abbreviations are used:

	DMSO	dimethyl sulphoxide;
	DMF	<i>N</i> -dimethylformamide;
	DCM	dichloromethane;
	NMP	<i>N</i> -methylpyrrolidinone;
5	DIAD	Di- <i>is</i> opropylazodicarboxylate
	LHMDS or LiHMDS	Lithium bis(trimethylsilyl)amide
	MeOH	Methanol
	RT	Room temperature
	TFA	Trifluoroacetic acid
10	EtOH	ethanol
	EtOAc	ethyl acetate.
	EDTA	ethylenediaminetetraacetic acid
	THF	tetrahydrofuran

15 **EXAMPLE 1.**

**R/S-5-[[[4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl]sulfonyl)methyl]-5-methylimidazolidine-2,4-dione**



20

A solution of 4-(2,5-dimethylbenzyloxy)piperidinylsulfonylpropan-2-one (prepared as described below) (210mg, 0.62mmol) in EtOH / H<sub>2</sub>O (20ml, 3:1) was added potassium cyanide (80mg, 1.23mmol) and ammonium carbonate (245mg, 3.10mmol). The mixture was heated at 70°C for 5h. Additional ammonium carbonate (1g, 12.6mmol) was added and the mixture stirred at RT for 17h. The mixture was then concentrated to approximately half the volume and extracted with EtOAc (2x10ml). The combined organic layers were partitioned



with brine (10ml), dried (MgSO<sub>4</sub>), concentrated and purified by chromatography (10g silica bond elute, eluent 20-100% EtOAc / Hexane) to give R/S-5-[(4-[(2,5-

dimethylbenzyl)oxy]piperidin-1-yl)sulfonyl)methyl]-5-methylimidazolidine-2,4-dione

as a white solid (30mg, 0.07mmol).

5 NMR: 1.3 (s, 3H), 1.6 (m, 2H), 1.9 (m, 2H), 2.2 (s, 3H), 2.25 (s, 3H), 3.0 (m, 2H), 3.3 (m, 3H), 3.5 (d, 1H), 3.6 (m, 1H), 4.5 (s, 2H), 7.0 (dd, 1H), 7.05 (dd, 1H), 7.1 (d, 1H), 8.0 (s, 1H), 10.7 (s, 1H).

MS (-ve) 408.

10 The starting material, 4-(2,5-dimethylbenzyloxy)piperidinylsulfonylpropan-2-one, was prepared as described below:

i) To a solution of *tert*-butyl 4-hydroxypiperidine-1-carboxylate (4g, 19.9mmol) in DMF (100ml) at RT was added sodium hydride (796mg, 60% dispersion in oil, 19.9mmol). After 1h 2,5-dimethylbenzyl chloride (2.94ml, 19.9mmol) was added dropwise. After 16h

15 water was added (5ml) and the DMF removed *in vacuo*. The mixture was partitioned between water (100ml) and DCM (3x200ml) and the combined organic layer was, dried (MgSO<sub>4</sub>), concentrated and purified by chromatography (MPLC, eluting with 0→20% EtOAc/ DCM) to give *tert*-butyl 4-(2,5-dimethylbenzyloxy)piperidine-1-carboxylate as a green oil (4.15g, 13mmol).

20 NMR: 1.4 (m, 11H), 1.8 (m, 2H), 2.2 (d, 6H), 3.0 (m, 2H), 3.6 (m, 3H), 4.4 (s, 2H), 7.0 (m, 2H), 7.1 (s, 1H); MS: 320.

ii) To a solution of *tert*-butyl 4-(2,5-dimethylbenzyloxy)piperidine-1-carboxylate (4.1g, 12.85mmol) in DCM (30ml) was added TFA (3ml) and the mixture stirred overnight at

25 RT. TFA (3ml) was added and the mixture stirred at 40°C. After 1h the mixture was concentrated and the residue azeotroped with toluene to give 4-(2,5-

dimethylbenzyloxy)piperidine.TFA salt as a colourless oil (5.52g, 12.85mmol plus a small amount of toluene).

NMR: 1.7 (m, 2H), 2.0 (m, 2H), 2.2 (s, 3H), 2.25 (s, 3H), 3.0 (m, 2H), 3.2 (m, 2H), 3.65 (m,


30 1H), 4.45 (s, 2H), 7.0 (m, 2H) and 7.1 (s, 1H); MS: 220.

iii) To a solution of 4-(2,5-dimethylbenzyloxy)piperidine.TFA salt (5.51g, 12.85mmol plus a small amount of toluene) in DCM (90ml) at 0°C was added triethylamine (8.59ml, 61.6mmol) followed by dropwise addition of methanesulphonylchloride (1.05ml, 13.6mmol) dropwise over 5mins and the reaction mixture was allowed to warm to RT. After 63h the mixture was diluted with DCM (90ml), washed with water (50ml), brine (50ml), dried (MgSO<sub>4</sub>) and concentrated to give a light brown oil. The oil was triturated with EtOH (20ml), filtered and washed with cold EtOH and concentrated to give 4-(2,5-dimethylbenzyloxy)piperidinylsulfonylmethane as a white solid (2.63g, 8.0mmol). NMR: 1.6 (m, 2H), 1.9 (m, 2H), 2.2 (s, 3H), 2.25 (s, 3H), 2.85 (s, 3H), 3.0 (m, 2H), 3.55 (m, 1H), 4.45 (s, 2H), 7.0 (m, 2H) and 7.1 (s, 1H); MS: 298.

iv) To a stirred solution of 4-(2,5-dimethylbenzyloxy)piperidinylsulfonylmethane (500mg, 1.68mmol) in THF (5ml) at 0°C, was added LHMDs (3.6ml, 3.6mmol). After 10 mins acetyl chloride (0.14ml, 1.96mmol) was added. After 2h sat. ammonium chloride (5ml) was added, the reaction warmed to RT and the product extracted with EtOAc (2x10ml). The combined organic layers were partitioned with brine (10ml), dried (MgSO<sub>4</sub>), concentrated and purified by chromatography (10g silica bond elute, eluent 0-50% EtOAc / Hexane) to give 4-(2,5-dimethylbenzyloxy)piperidinylsulfonylpropan-2-one as an oily residue (210mg, 0.62mmol). MS (-ve) 338

## EXAMPLE 2

R/S-5-[(4-(2-methylquinolin-4-yl methoxy)piperidin-1-yl)sulfonyl)methyl]-5-methylimidazolidine-2,4-dione



To a solution of 4-(2-methylquinolin-4-yl methoxy)piperidinylsulfonylpropan-2-one (prepared as described below) (206mg, 0.547mmol) in EtOH / H<sub>2</sub>O (10ml, 1:1) was added potassium cyanide (69mg, 1.09mmol) and ammonium carbonate (875mg, 3.28mmol). The mixture was heated at 65°C for 2h. The mixture was then concentrated to approximately half the volume and extracted with EtOAc (3x10ml). The combined organic layers were partitioned with brine (10ml), dried (MgSO<sub>4</sub>) and concentrated to give a yellow solid. This was recrystallised from hot EtOAc/iso-hexane to give R/S-5-[(4-(2-methylquinolin-4-yl methoxy)piperidin-1-yl)sulfonyl)methyl]-5-methylimidazolidine-2,4-dione as a white solid (215mg, 0.482mmol).

10 NMR: 1.3 (s,3H), 1.65 (m,2H), 2.0 (m,2H), 2.7 (s,3H), 3.05 (m,2H), 3.7 (m,1H), 5.0 (s,2H), 7.45 (s,1H), 7.55 (m,1H), 7.7 (m,1H), 7.9 (m,1H), 8.1 (m,2H).

MS (-ve) 445.

The starting material, 4-(2-methyl-quinolin-4-yl methoxy)piperidinylsulfonylpropan-2-one, was prepared as described below:

15 i) To a stirred suspension of 2-methylquinoline-4-carboxylic acid (4g, 21.4mmol) in THF (100ml) at RT was added lithium aluminium hydride (21.4ml, 1.0M solution in THF, 21.4mmol) dropwise over 20mins. After 16h water (4ml) was added cautiously followed by 2N NaOH (4ml) and water (12ml). The resulting gelatinous precipitate was filtered off and washed with THF. DCM (200ml) was added to the filtrate and partitioned with saturated NaHCO<sub>3</sub> (2x75ml). The organic layer was dried (MgSO<sub>4</sub>), concentrated, triturated with DCM & filtered to give 2-methylquinoline-4-methylalcohol as a white powder (858mg, 5mmol).

The mother liquours were purified by chromatography (20g silica bond elute, eluent 0→5% EtOH / DCM) to give a further 610mgs of product (3.5mmol).

25 NMR: 2.6 (s, 3H), 5.0 (d, 2H), 5.5 (t, 1H), 7.4 (s, 1H), 7.5 (t, 1H), 7.7 (t, 1H) and 7.9 (m, 2H); MS: 174.

ii) To a suspension of 2-methylquinoline-4-methylalcohol (100mg, 0.58mmol) in DCM (5ml) at RT was added triethylamine (0.24ml, 1.74mmol). The reaction mixture was then cooled to 0°C and methanesulphonylchloride (0.05ml, 0.64mmol) was added dropwise. 30 After 10mins the reaction mixture was concentrated and EtOAc (20ml) was added and the organic layer partitioned with brine (10ml), dried (MgSO<sub>4</sub>), concentrated and purified by

chromatography (10g silica bond elute, eluent 5% MeOH / DCM) to give 2-methylquinoline-4-methoxysulphonylmethane (110mg, 0.44mmol).

NMR: 2.7 (s, 3H), 3.35 (s, 3H), 5.75 (s, 2H), 7.5 (s, 1H), 7.6 (t, 1H), 7.75 (t, 1H), 8.0 (m, 2H); MS: 252.

5

iii) To a solution of *tert*-butyl 4-hydroxypiperidine-1-carboxylate (1.75g, 8.73mmol) in DMF (20ml) at 0°C was added sodium hydride (419mg, 60% dispersion in oil, 10.5mmol).

After 10mins a solution of 2-methylquinoline-4-methoxysulphonylmethane (2.19g, 8.73mmol) in DMF (10ml) was added dropwise over 5mins at 0°C. After 5h the mixture was

10 concentrated and the residue taken up in EtOAc (150ml). The organic layer was washed with brine (50ml), dried (Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>), concentrated and purified by chromatography (MPLC, eluting with 75% EtOAc/ hexane) to give *tert*-butyl 4-(2-methylquinoline-4-methoxy)piperidine-1-carboxylate (1.46g, 4.1mmol).

MS: 357.

15

iv) To a solution of *tert*-butyl 4-(2-methylquinoline-4-methoxy)piperidine-1-carboxylate (1.45g, 4.1mmol) in DCM (10ml) at RT was added TFA (3ml). After 15h the mixture was concentrated and azeotroped with toluene (x2) to give 4-(2-methylquinoline-4-methoxy)-piperidine.di TFA salt (1.97g, 4.1mmol).

20 MS: 257.

v) To a solution of 4-(2-methylquinoline-4-methoxy)-piperidine.di TFA salt (2.49g, 5.2mmol) in DCM (40ml) at 0°C was added triethylamine (4.3ml, 31mmol) followed by dropwise addition of methanesulphonylchloride (0.8ml, 10.3mmol) dropwise over 1min and

25 the reaction mixture was allowed to warm to RT. After 15h the mixture was diluted with DCM (60ml), washed with water (30ml), brine (25ml), concentrated and purified by chromatography (MPLC, eluting with 100% EtOAc) to give 4-(2-methylquinoline-4-methoxy)-piperidinylnsulphonylmethane (600mg, 1.8mmol) as a pale yellow solid.


30 NMR: 1.6 (m, 2H), 2.0 (m, 2H), 2.65 (s, 3H), 2.85 (s, 3H), 3.0 (m, 2H), 3.3 (m, 2H), 3.7 (m, 1H), 5.0 (s, 2H), 7.4 (s, 1H), 7.5 (t, 1H), 7.7 (t, 1H), 7.9 (d, 1H) and 8.0 (d, 1H); MS: 335.

vi) To a stirred solution of 4-(2-methylquinoline-4-methoxy)-  
piperidinylsulphonylmethane (400mg, 1.06mmol) in dry THF (10ml) at approximately -16°C,  
was added LHMDS (2.63ml, 2.34mmol). After 30 min. ethyl acetate (0.1ml, 1.06mmol) was  
added and the reaction warmed to RT. After 2h sat. ammonium chloride (10ml) was added,  
5 the reaction warmed to RT and the product extracted with EtOAc (3x20ml). The combined  
organic layers were partitioned with brine (10ml), dried (MgSO<sub>4</sub>) and concentrated to give  
0.36g as a yellow oil. This was titrated with iso-hexane to give 4-(2-methyl-quinolin-4-yl  
methoxy)piperidinylsulfonylpropan-2-one as a white solid (206mg, 0.547mmol).  
NMR: 1.65 (m,2H), 1.9 (m,2H), 2.2 (s,2H), 2.6 (s,3H), 3.0 (m,2H), 3.35 (m,2H), 3.6 (m,1H),  
10 4.9 (s,2H), 7.4 (s,1H), 7.5 (t,1H), 7.6 (t,1H), 7.85 (d, 1H), 8.0 (d,1H).  
MS (+ve) 377.

CLAIMS

We claim:

1. A compound of formula (1), a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof:



formula (1)

10 wherein:

$Y^1$  and  $Y^2$  are independently O or S;

z is  $NR^8$ , O or S;

15 n is 0 or 1;

W is  $NR^1$ ,  $CR^1R^2$  or a bond;

m is 0 or 1;

20

D is hydrogen,  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl or fluoro;

$X_{1-5}-(CR^{12}R^{13})_t-Q-(CR^{14}R^{15})_u-$  where t and u are independently 0 or 1 and Q is O, S, SO or  $SO_2$ ;

25

where a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_2$ -

- 4alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by
- 5  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-$
- 10  $NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl and  $C_{1-4}$ alkoxy; with the provisos that:  
when n is 1 and W is  $NR^1$ ,  $CR^1R^2$  or a bond; or when n is 0 and W is  $CR^1R^2$ ; then B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{2-}$
- 15 4alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-$
- 20  $NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-$   $NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl and  $C_{1-4}$ alkoxy; and
- 25 when n is 0 and W is  $NR^1$  or a bond; then B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl
- 30 (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-$

- $\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $-\text{NHCONR}^9\text{R}^{10}$ ,  $-\text{OR}^9$ ,  $-\text{NR}^9\text{R}^{10}$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ; or B is  $\text{C}_{2-4}$ alkenyl or  $\text{C}_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $\text{C}_{1-4}$ alkyl,  $\text{C}_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl whereby this group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,   
 5  $\text{CONHR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $\text{C}_{1-4}$ alkyl and  $\text{C}_{1-4}$ alkoxy;

$\text{R}^1$  and  $\text{R}^2$  are independently hydrogen or a group selected from  $\text{C}_{1-6}$ alkyl,  $\text{C}_{2-6}$ alkenyl,  $\text{C}_{2-6}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl and  $\text{C}_{5-6}$ cycloalkenyl where the group may be optionally substituted by halo, cyano, nitro, hydroxy or  $\text{C}_{1-4}$ alkoxy;

10

$\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$  and  $\text{R}^6$  are independently hydrogen or a group selected from  $\text{C}_{1-6}$ alkyl,  $\text{C}_{2-6}$ alkenyl,  $\text{C}_{2-6}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl,  $\text{C}_{5-6}$ cycloalkenyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{2-4}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl (optionally substituted by one or more  $\text{R}^{17}$ ), aryl (optionally substituted by one or more  $\text{R}^{17}$ ), heteroaryl (optionally substituted by one or more  $\text{R}^{17}$ ), heterocyclyl,  $-\text{OR}^{18}$ ,  $-\text{SR}^{19}$ ,  $-\text{SOR}^{19}$ ,  $-\text{SO}_2\text{R}^{19}$ ,  $-\text{COR}^{19}$ ,  $-\text{CO}_2\text{R}^{18}$ ,  $-\text{CONR}^{18}\text{R}^{20}$ ,  $-\text{NR}^{16}\text{COR}^{18}$ ,  $-\text{SO}_2\text{NR}^{18}\text{R}^{20}$  and  $-\text{NR}^{16}\text{SO}_2\text{R}^{19}$ ;

- 15  $-\text{SOR}^{19}$ ,  $-\text{SO}_2\text{R}^{19}$ ,  $-\text{COR}^{19}$ ,  $-\text{CO}_2\text{R}^{18}$ ,  $-\text{CONR}^{18}\text{R}^{20}$ ,  $-\text{NR}^{16}\text{COR}^{18}$ ,  $-\text{SO}_2\text{NR}^{18}\text{R}^{20}$  and  $-\text{NR}^{16}\text{SO}_2\text{R}^{19}$ ;

- 20 or  $\text{R}^1$  and  $\text{R}^3$  together with the nitrogen or carbon and carbon to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $\text{SO}_2$  where the ring is optionally substituted by one or more  $\text{C}_{1-4}$ alkyl;

- 25 or  $\text{R}^3$  and  $\text{R}^4$  together form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $\text{SO}_2$  where the ring is optionally substituted by one or more  $\text{C}_{1-4}$ alkyl;

- or  $\text{R}^5$  and  $\text{R}^6$  together form a saturated 3- to 7-membered ring optionally containing 1 or 2  
 30 heteroatom groups selected from NH, O, S, SO and  $\text{SO}_2$  where the ring is optionally substituted by one or more  $\text{C}_{1-4}$ alkyl;



- $R^7$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, heteroalkyl,  $C_{3-7}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-7}$ cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group
- 5 and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, carboxy $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-SR^{25}$ ,  $-SOR^{25}$ ,  $-SO_2R^{25}$ ,  $-NR^{21}COR^{22}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;
- 10 or  $R^3$  and  $R^7$  together with the carbon atoms to which they are each attached and  $(CR^5R^6)_n$  form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon or nitrogen by one or more  $C_{1-4}$ alkyl;
- 15  $R^8$  is selected from hydrogen,  $C_{1-6}$ alkyl and halo $C_{1-6}$ alkyl;
- $R^9$  and  $R^{10}$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;
- or  $R^9$  and  $R^{10}$  together with the nitrogen to which they are attached form a heterocyclic 4 to 7-
- 20 membered ring.
- $R^{11}$  is  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;
- $R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl;
- 25  $R^{16}$  is hydrogen or  $C_{1-6}$ alkyl;
- $R^{17}$  is selected from halo,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl and  $C_{1-6}$ alkoxy;
- 30  $R^{18}$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{5-7}$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl where the group is optionally substituted by one or more halo;

$R^{19}$  and  $R^{25}$  are independently a group selected from  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{5-7}$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl where the group is optionally substituted by one or more halo;

5

$R^{20}$  is hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

or  $R^{18}$  and  $R^{20}$  together with the nitrogen to which they are attached form a heterocyclic 4- to 7- membered ring;


10

$R^{21}$  and  $R^{22}$  are independently hydrogen,  $C_{1-4}$ alkyl, halo $C_{1-4}$ alkyl, aryl, aryl $C_{1-4}$ alkyl and benzoyl;

or  $R^{21}$  and  $R^{22}$  together with the nitrogen to which they are attached form a heterocyclic 5- to 6- membered ring.

15

2. A compound of formula (1), a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof:



20

formula (1)

wherein:

$Y^1$  and  $Y^2$  are independently O or S;

25  $Z$  is  $NR^8$ , O or S;

$n$  is 0;

W is  $\text{NR}^1$  or a bond;

---

m is 0 or 1;

5 D is hydrogen,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{3-6}$ cycloalkyl or fluoro;

X is  $-(\text{CR}^{12}\text{R}^{13})_t-\text{Q}-(\text{CR}^{14}\text{R}^{15})_u-$  where t and u are independently 0 or 1 and Q is O, S, SO or  $\text{SO}_2$ ;

- 10 B is a group selected from aryl, heteroaryl and heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $\text{C}_{1-4}$ alkyl (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{2-4}$ alkenyl (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{2-4}$ alkynyl (optionally substituted by halo or  $\text{R}^9$ ),  $\text{C}_{3-6}$ cycloalkyl (optionally substituted by  $\text{R}^9$  or one or more halo),  $\text{C}_{5-6}$ cycloalkenyl (optionally substituted by halo or  $\text{R}^9$ ), aryl (optionally substituted by halo or  $\text{C}_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $\text{C}_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $\text{C}_{1-4}$ alkyl),  $-\text{SR}^{11}$ ,  $-\text{SOR}^{11}$ ,  $-\text{SO}_2\text{R}^{11}$ ,  $-\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $-\text{NR}^9\text{SO}_2\text{R}^{11}$ ,  $-\text{NHCONR}^9\text{R}^{10}$ ,  $-\text{OR}^9$ ,  $-\text{CONR}^9\text{R}^{10}$  and  $-\text{NR}^9\text{COR}^{10}$ ;
- 20  $\text{R}^1$  is hydrogen or a group selected from  $\text{C}_{1-6}$ alkyl,  $\text{C}_{2-6}$ alkenyl,  $\text{C}_{2-6}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl and  $\text{C}_{5-6}$ cycloalkenyl where the group may be optionally substituted by halo, cyano, nitro, hydroxy or  $\text{C}_{1-4}$ alkoxy;

$\text{R}^3$  and  $\text{R}^4$  are independently hydrogen or a group selected from  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{2-4}$ alkynyl,  $\text{C}_{3-5}$ cycloalkyl, pentenyl, aryl, heteroaryl and heterocyclyl where the group is

- 25 optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{2-4}$ alkynyl,  $\text{C}_{3-6}$ cycloalkyl (optionally substituted by one or more  $\text{R}^{17}$ ), aryl (optionally substituted by one or more  $\text{R}^{17}$ ), heteroaryl (optionally substituted by one or more  $\text{R}^{17}$ ), heterocyclyl,  $-\text{OR}^{18}$ ,  $-\text{SR}^{19}$ ,  $-\text{SOR}^{19}$ ,  $-\text{SO}_2\text{R}^{19}$ ,  $-\text{CONR}^{18}\text{R}^{20}$  and  $-\text{NR}^{16}\text{COR}^{18}$ ;
- 30

or  $R^1$  and  $R^3$  together with the nitrogen or carbon and carbon to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon or nitrogen by one or more  $C_{1-4}$ alkyl;

5

or  $R^3$  and  $R^4$  together form a carbocyclic or saturated heterocyclic 3- to 7-membered ring optionally containing 1 or 2 heteroatom groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon or nitrogen by one or more  $C_{1-4}$ alkyl;

10  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, heteroalkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-5}$ cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, carboxy $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-SR^{25}$ ,  $-SOR^{25}$ ,  $-SO_2R^{25}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;

15  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, heteroalkyl,  $C_{3-5}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-5}$ cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-5}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, carboxy $C_{1-4}$ alkyl,  $-OR^{21}$ ,  $-CO_2R^{21}$ ,  $-SR^{25}$ ,  $-SOR^{25}$ ,  $-SO_2R^{25}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;

or  $R^3$  and  $R^7$  together with the carbon atoms to which they are each attached and  $(CR^5R^6)_n$   
20 form a saturated carbocyclic or heterocyclic 5- or 6-membered ring;

$R^8$  is selected from hydrogen,  $C_{1-4}$ alkyl and halo $C_{1-4}$ alkyl;

$R^9$  and  $R^{10}$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

25

or  $R^9$  and  $R^{10}$  together with the nitrogen to which they are attached form a heterocyclic 4 to 6-membered ring.

$R^{11}$  is  $C_{1-4}$ alkyl or  $C_{3-5}$ cycloalkyl;

$R^{12}$ ,  $R^{13}$ ,  $R^{14}$  and  $R^{15}$  are independently selected from hydrogen,  $C_{1-4}$ alkyl and  $C_{3-4}$ cycloalkyl;

R<sup>16</sup> is hydrogen or C<sub>1-4</sub>alkyl;

R<sup>17</sup> is selected from halo, C<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl and C<sub>1-4</sub>alkoxy;

5 R<sup>18</sup> is hydrogen or a group selected from C<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is optionally substituted by one or more halo;

R<sup>19</sup> and R<sup>25</sup> are independently a group selected from C<sub>1-4</sub>alkyl, C<sub>3-5</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl  
10 where the group is optionally substituted by one or more halo;

R<sup>20</sup> is hydrogen, C<sub>1-4</sub>alkyl or C<sub>3-5</sub>cycloalkyl;

15 or R<sup>18</sup> and R<sup>20</sup> together with the nitrogen to which they are attached form a heterocyclic 4- to 6- membered ring;

R<sup>21</sup> and R<sup>22</sup> are independently hydrogen, C<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkyl, aryl, arylC<sub>1-4</sub>alkyl and benzoyl;

20

or R<sup>21</sup> and R<sup>22</sup> together with the nitrogen to which they are attached form a heterocyclic 5- to 6- membered ring.

3. A compound according to Claim 1 or Claim 2, for use as a medicament.


25

4. The use of a compound according to Claim 1 or Claim 2 in the manufacture of a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes.

30 5. The use of a compound according to Claim 1 or Claim 2 in the manufacture of a medicament in the treatment of a disease condition mediated TNF- $\alpha$ .

6. A pharmaceutical composition comprising a compound according to Claim 1 or Claim 2; and a pharmaceutically-acceptable diluent or carrier.

7. A process for preparing a compound according to Claim 1 or Claim 2, comprising the 5 steps of converting a ketone or aldehyde of formula (2) into a compound of formula (1);



10 and thereafter if necessary:

- i) converting a compound of the formula (1) into another compound of the formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

**THIS PAGE BLANK (USPTO)**

PCT Application

**GB0303937**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**